Introduction
Current treatment options for astrocytic gliomas, are limited to surgical resection, radiation therapy and chemotherapy, and these modalities are frequently inadequate. A better understanding of the molecular mechanisms and microenvironmental factors that drive glioma tumor growth are required to promote developments of more effective therapies for glioma patients. One major factor that contributes to enhanced glycolysis is adaptation to hypoxia in the tumor microenvironment (1) . Hypoxia in tumors triggers molecular responses that promote an aggressive cancer phenotype, and intratumoral hypoxia has been associated with a poor clinical outcome for many cancers (2) (3) (4) . Furthermore, hypoxic tumor cells also contribute to resistance, radiation and chemotherapy (5,6), and hypoxia regulates several important tumor growth-promoting cellular mechanisms, such as angiogenesis, cellular proliferation, genomic instability, and tumor invasion (7) .
Carbonic anhydrase 9 (CA9) is induced by hypoxia in a wide range of tumors, and it is usually suppressed under normoxic conditions (8) (9) (10) (11) . Expressed CA9 colocalizes with pimonidazole, a chemical marker of hypoxia, and its expression is usually restricted to perinecrotic areas (8, 12) , which make CA9 an attractive endogenous marker of tumor hypoxia. Furthermore, CA9 expression has been associated with a poor prognosis in lung, breast, and cervical cancer (13) (14) (15) , and with resistance to chemotherapy in head and neck cancers (16) . Previously, we reported that CA9 is associated with anaplastic phenotypes in meningioma and suggested that it is an indicator of a poor prognosis in affected patients (17) . However, the association between CA9 and astrocytic glial tumor grade, and its prognostic value in human astrocytic gliomas have not been well investigated.
The formation of primitive blood vessels from progenitors, such as hemangioblasts and angioblasts, is dependent on vascular endothelial growth factor (VEGF) and the VEGF receptor system (18) . Malignant glioma cells secrete a variety of angiogenic factors such as VEGF and basic fibroblast growth factor (FGF) (19) . Furthermore, VEGF has been considered to play a major role in the angiogenesis, as suggested of other solid tumors such as colon and breast carcinomas (20) , and VEGF expression has been shown to influence the outcomes of other tumors (21) (22) (23) . However, the relation between VEGF and WHO tumor grade and the effect of VEGF expression on prognosis has not been investigated in depth for astrocytic gliomas.
Materials and methods
Patients. We analyzed 78 pathologically confirmed astrocytic gliomas with archived tissues available for immunohistochemistry staining. Of the 78 tumors 14 were WHO grade II, 30 were grade III, and 34 were grade IV. Of the 78 patients 42 were male, and 56 patients were <60 years old. CA9 was positive in 40 patients, and negative in 38. VEGF was positive in 33 patients and negative in 43 (Table I) .
Tumor samples and immunohistochemistry. Slides stained with hematoxylin and eosin (H&E) retained tissues were reviewed by a neuropathologist (H.S. Min). Immunohistochemical staining was performed automatically using Benchmark XT (Roche, Switzerland) which utilized the conventional streptavidin-biotinperoxidase method, as recommended by the manufacturer. CA9 (Novus, Polyclonal, 1:1,000) and VEGF (BD Pharmingen, G153-694, 1:500) primary antibodies were used. Staining intensities of CA9 positive cells in tumor parenchyma were assessed using an arbitrary scoring system ( Fig. 1 ) and CA9 staining scores were calculated by multiplying positive cell percentage scores (1, <10%; 2, 10%-50%; 3, >50%) by intensity scores (0, null; 1, weak; 2, moderate; 3, strong). CA9 expression was considered negative when CA9 staining scores were 0 or 1, and positive when scores were >1. For VEGF, positive immunoexpression was graded as +1, +2, or +3 based on staining intensity (Fig. 2) . VEGF scores of 0 or 1 were considered negative for VEGF expression and scores of 2 or 3 were considered positive.
Statistical analysis. Pearson's correlation coefficients were used to examine correlations between CA9 and VEGF scores and tumor grades. For survival analysis, overall survival was defined as time from date of surgery until death, which was considered an event in the analysis. Univariate and multivariate Coxregression analysis, Kaplan-Meier survival analysis, the logrank test, Wilcoxon's (Breslow's) test, and Spearman's correlation were used.
Statistical analysis was performed using Stata 10 software (Stata Corporation Station, TX, USA). Statistical significance was accepted for a p-value of 0.05.
Ethics. The study protocol was approved by the Institutional Review Board of the National Cancer Center, Korea. (Protocol number NCCNCS-09-227).

Results
Univariate Cox-regression survival analysis. Survival analysis was performed on age, gender, CA9, VEGF, WHO grade. The parameters found to adversely affect survival time were age, CA9 positivity, and WHO grade (Table IIA) .
Multivariate Cox-regression survival analysis. We considered that age, CA9, VEGF, and WHO grade potentially affected survival time based on the results of univariate Cox-regression analysis. Multivariate Cox-regression analysis was performed for CA9, and VEGF separately, and both analyses showed that histologic grade was the only factor that significantly affected survival (Table IIB Table I . Clinical characteristics. and WHO grade was also significant (Pearson's correlation coefficient = 7.0, p=0.03). However, CA9 and VEGF positivity did not correlate with each other (p=0.17).
Survival according to CA9 expressions. Survival analysis was performed by Kaplan-Meier curve analysis using the CA9 scores of all 78 tumors. Median survival time was 50.4 months for CA9 negative patients, but 12.0 months for CA9-positive patients, and these survival times were significantly different (p=0.004) (Fig. 3A) .
Survival analysis was also performed for WHO grade II, III, and IV tumors separately. Median survival time was not reached for CA9-negative grade II patients, and 31 months for CA9-positive grade II patients. Similarly, median survival times for grade III patients, were 50.8 and 22.3 months for CA9-negative and -positive patients, and median survival times for grade IV patients were 4.8 and 9.6 months for CA9-negative and -positive patients.
For grade II patients, survival times were significantly different for CA9-positive and -negative patients (p=0.01) (Fig. 3B) . However, this was not the case for grade III, or IV patients who were not significantly different between CA9-positive and -negative group in WHO grade III and IV patients (grade III, p=0.6; grade IV, p=0.5).
Survival according to VEGF expression. Survival analysis was performed using the Kaplan-Meier method according to VEGF grade for all 78 tumors. Median survival times were 26.8 and 14.4 months in VEGF-negative and -positive patients, respectively. However, this difference was not significant (p=0.1) (Fig. 4) .
Discussion
Currently, the importance of the role played by hypoxia in the biology of tumors is evident. Research efforts continue to identify intrinsic markers of hypoxia and both CA9 and VEGF are known to be products of hypoxia-induced pathways. CA9 is a transmembrane protein, and converts carbon dioxide to bicarbonate and hydrogen, and thus regulates microenvironmental pH, and influences other processes such as cell to cell adhesion, cellular proliferation, and tumor cell invasion (24) . Correlations between clinical outcomes and CA9 expression have been reported for several malignancies such as for cervix (25) , lung (13), breast (26) , kidney (27) and head and neck (28) . Furthermore, CA9 expression has been associated with poorer relapse-free and overall survival in invasive breast carcinoma (14) , and in small cell lung cancer, CA9-positive tumors have been reported to be associated with a significantly shorter overall survival (13) . Previously, we suggested that CA9 is a prognostic factor in meningioma (17) . Thus, CA9 expression clearly has prognostic significance in a variety of human tumors.
In the present study, the CA9 positive rate among patients with an astrocytic glioma was found to increase significantly Table II . Survival analysis. 
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as WHO grade increased. Furthermore, CA9 positivity was found to be associated with poor survival for all WHO grades. In the present study, CA9 was found to be expressed in perinecrotic tumoral regions which suggests that CA9 expression is induced by hypoxic conditions in human brain astrocytic glioma. Degree of necrosis increases with WHO grade and typically perinecrotic regions within tumors are hypoxic. However, CA9 expression may not precisely mimic oxygen concentrations as measured by microelectrodes or by bioreductive drugs. In the present study, our separate analysis of WHO grade II, III, and IV tumors, showed that survival times were significantly different according to CA9 status for WHO grade II tumors, but not for WHO grade III, and IV tumors. Furthermore, the survival time of CA9-negative tumors was significantly greater than that of CA9-positive tumors, which is possibly because survival times or patients with a WHO grade III and IV tumor were primarily influenced by factors other than CA9 status.
Relations between CA9 expressional status and hypoxia or pH may explain the correlation between CA9 expressional status and tumor grade. CA9 expression is the response to hypoxia mediated by HIF-1 transcription factor and its levels in tumor tissues have been reported to provide a measure of chronic hypoxia (8) . Furthermore, tumor cell proliferation involves the consumption of oxygen and leads to increased acid production (29) , and CA9 upregulation under hypoxic conditions eliminates this acid load and endows tumor cells with a survival advantage which contributes to the acquisition of a more aggressive phenotype (30) . These findings suggest that CA9 is a marker of tumor aggressiveness. In the present study, univariate analysis indicated that CA9 is a prognostic factor of survival, but multivariate analysis identified WHO grade as the only significant prognostic factor. These findings suggest that CA9 expression is a separate indicator of brain tumor survival, which does not reflect the same features as WHO grade, and that thus, perhaps CA9 expression should be considered as another classification criterion for astrocytic glioma.
Malignant glioma is a highly vascularized tumor and its microvascular density has been reported to be correlated with a poor clinical prognosis. Furthermore, malignant glioma cells secrete a variety of angiogenic factors such as VEGF and basic FGF (19) . Furthermore, VEGF has been considered to play a major role in angiogenesis and is a prognostic factor for other solid tumors such as those of colon cancer and breast carcinoma (22, 31) . In the present study, VEGF expression was found to be significantly correlated with WHO tumor grade, but this significance was weaker than that found for CA9 expression. These findings are similar to those of a previous report in which VEGF expression was found to be significantly higher in glioblastoma than in low grade glioma, however the strength of these relations were weaker than those of CA9 expression (32) . During our survival analysis, the survival of patients with a VEGF-negative tumor was found to be non-significantly greater than that of those with a VEGFpositive tumor (p=0.1). Furthermore, VEGF expression was not found to be a significant factor of survival time by univariate and multivariate regression analysis, which indicates that a larger scale study is needed to determine the effect of VEGF on survival. In addition, our findings concur with a Table III . Correlation between CA9, VEGF and WHO grade. previous report that the prognostic significance of VEGF expression did not withstand multivariate analysis (30) .
At least four mechanisms have been suggested for the upregulation of VEGF gene expression in glioma. One involves a hypoxia/HIF-related mechanism in growing glioma tissues and another a HuR protein-related mechanism. According to this mechanism, VEGF is related with hypoxia and CA9. The other two mechanisms involve the EGFR signaling pathway and FoxM1B transcription factor. The EGFR signaling pathway stimulates VEGF gene expression via a HIF-independent mechanism, and it has been reported that FoxM1B is upregulated in glioblastoma multiform tissues, but not in lowgrade astrocytoma tissues, and that it stimulates VEGF expression independently of HIF (33) . Furthermore, it has been argued that different degrees of hypoxia are required for induction of VEGF and CA9 and that CA9 induction requires more severe hypoxia. Thus, the presence of CA9 expression reflects exposure to prolonged hypoxia (13) . These findings help explain why VEGF expression was not found to be correlated with CA9 expression and is less significantly related to WHO grade than CA9.
Likewise, in the present study, we found that VEGF was not an independent prognostic factor of survival. Bevacizumab in combination with cytotoxic agents such as irinotecan, and other anti-angiogenic drugs such as VEGF-Trap has recently been reported to suppress tumor growth and improve survival in malignant glioma patients during phase II clinical trials (34, 35) . These drugs require further investigation to prove their abilities to enhance survival, and in addition, more study of drugs targeting CA9 is warranted.
In summary, we found that intratumoral CA9 expression is associated with WHO grade in astrocytic gliomas, and that it is possibly an independent prognostic factor of overall survival. Furthermore, VEGF expression was found to be correlated with WHO grade, but not found to be a prognostic factor of overall survival. Our findings suggest that therapeutic strategies for the treatment of glioma involving the targeting of CA9 are required and that therapied targeting VEGF require more investigation. In addition, VEGF expression was not found to be correlated with CA9 expression, which suggests that VEGF is produced independently of CA9. Finally, we suggest that further study be undertaken to determine the correlation between CA9 and clinical outcome in patients with astrocytic glioma of the brain.
